BJMO - volume 10, issue 7, november 2016
P. Specenier MD, PhD
Overview of Belgian reimbursement news.
(BELG J MED ONCOL 2016;10(7):285)
Read moreBJMO - volume 10, issue 3, october 2016
P. Specenier MD, PhD
Cancer immunology is living its Golden Age.1,2 The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor ipilimumab (Yervoy®) has been approved for the treatment of advanced melanoma by FDA and EMA, and, at a dose of 10 mg/kg, for the adjuvant treatment of stage III melanoma by FDA.3,4 The inhibitors of the programmed cell-death protein 1 (PD-1) nivolumab and/or pembrolizumab have been approved by FDA and/or EMA, or have received a positive CHMP opinion for the treatment of advanced melanoma, advanced non-small cell lung cancer (NSCLC), and metastatic renal cell carcinoma.3,4 The anti-PDL1 inhibitor atezolizumab is under accelerated FDA review for advanced urothelial carcinoma which had disease progression after platinum-based chemotherapy, and prolongs survival in second line NSCLC patients.5,6 Nivolumab prolongs survival as second line treatment in Squamous Cell Carcinoma of the Head and Neck (SCCHN).7 Over 450 trials with atezolizumab, pembrolizumab, or nivolumab are registered at clinicaltrials.gov.8 More than 40 randomized phase III trial are planned or recruiting patients with NSCLC, advanced small cell lung cancer, multiple myeloma, Hodgkin lymphoma, SCCHN, gastric or gastroesophageal junction adenocarcinoma, esophageal carcinoma, hepatocellular carcinoma, urothelial cancer, triple negative breast cancer, colorectal cancer, glioblastoma, and renal cell carcinoma. All these phase III trials are planned to be completed by the end of 2020.8
Read moreBJMO - volume 10, issue 6, september 2016
P. Specenier MD, PhD
Overview of Belgian reimbursement news.
(BELG J MED ONCOL 2016;10(6):236)
Read moreBJMO - volume 10, issue 5, august 2016
P. Specenier MD, PhD
(BELG J MED ONCOL 2016;10(5):186–189)
Read moreBJMO - volume 10, issue 3, may 2016
P. Specenier MD, PhD
Overview of Belgian reimbursement news.
(BELG J MED ONCOL 2016;10(3):110)
Read moreBJMO - volume 10, issue 2, april 2016
P. Specenier MD, PhD, Tom Feys MBA, MSc
Overview of Belgian reimbursement news.
(BELG J MED ONCOL 2016;10(2):81)
Read moreBJMO - volume 10, issue 1, february 2016
P. Specenier MD, PhD
Overview of Belgian reimbursement news.
(BELG J MED ONCOL 2016;10(1):44),/p>
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
